Objective: To evaluate the potential contribution of urinary fluorescent in situ hybridization in the prediction of the risk of recurrence and progression of men undergoing follow-up for NMIBC Materials and Methods: Patients with a history of NMIBC being followed with urinary cytology and cystoscopy were included in the study. Patients with Carcinoma in situ or tumour stage higher than pT1 were excluded from this analysis. F.l.S.H. Test consisted in the Urovysion kit, able to detect four chromosomal abnormalities, specifically, 9p21, Ch 3, 7 and 17. Results: Of a total of 133 evaluable patients that constitute the subject of the present report 87 patients had a positive urinary F.l.S.H. At a median follow up time of 36 mos 58 patients underent recurrence (43.6%). In this group 42 (72.6%) and 27 (46.6%) patients had a positive F.l.S.H. and UC, respectively (p = 0.005). A total of 17 patients (12.8%) underwent progression of stage or grade; of those with a positive F.l.S.H. Test and positive UC were 14 (82.4%) and 8 (47.1 %), respectively (p = 0.049). Conclusion: In patients with history of NMIBC, F.l.S.H. showed a statistically significantly greater capability that UC in identifying patients with recurrence and progression of disease.
|Number of pages||5|
|Journal||Archivio Italiano di Urologia e Andrologia|
|Publication status||Published - Dec 2008|
- Fluorescence in situ hybridization
- Non-muscle invasive bladder cancer
- Urinary cytology
ASJC Scopus subject areas